Manufacturing Processes of Medical, Dental, and Biological Technologies (SBIR R43/R44) | Apply Online

FAQs: Manufacturing Processes of Medical, Dental, and Biological Technologies (SBIR R43/R44) - PA-09-113

What is the goal of this NIH SBIR funding opportunity?

The opportunity is designed to help move biomedical innovation into real-world, scalable manufacturing. It focuses on U.S. small businesses that are tackling the practical challenges that appear when a medical, dental, or biological technology must be produced reliably, at high quality, and at meaningful scale (not just invented or prototyped).

What is the Funding Opportunity Number (FOA) for this announcement?

The Funding Opportunity Number is PA-09-113.

Which organization is offering this opportunity?

The opportunity is offered through the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) program.

What grant mechanisms does this FOA use?

This announcement uses the SBIR grant mechanisms R43/R44, supporting Phase I, Phase II, and Fast Track applications.

What is supported under Phase I?

Phase I generally supports early feasibility and proof-of-concept work to demonstrate that the proposed manufacturing-focused approach is technically viable.

What is supported under Phase II?

Phase II generally supports more extensive research and development aimed at advancing the work toward commercialization, including stronger development of the manufacturing process, equipment, systems, and repeatable output quality.

What is the Fast Track option?

Fast Track is intended to accelerate projects that can justify a strong, continuous plan from Phase I into Phase II, reducing the administrative gap between phases.

What types of projects are within the scope of this manufacturing-focused FOA?

The scope centers on biomedical R&D tied to advanced processing and manufacturing. This includes improvements in manufacturing processes, equipment, and systems used for medical, dental, or biological technologies, especially work that improves quality, throughput, reproducibility, and safety in production settings.

Does the opportunity emphasize manufacturing readiness and scale-up?

Yes. The intent is to reduce the gap between a promising biomedical concept and a manufacturable product or platform, including the practical steps needed for reliable production and meaningful scaling.

Are workforce skills and worker protection part of the scope?

Yes. The announcement highlights manufacturing workforce skills and protection, signaling interest in approaches that improve how manufacturing is performed and controlled, how workers are trained and safeguarded, and how consistent output is maintained in high-reliability or regulated environments typical of healthcare products.

Are there narrow topic constraints listed in the summary provided?

No. The provided summary does not list narrow topic constraints, but the clear intent is to fund manufacturing-focused work that improves practical producibility of biomedical technologies.

Who is eligible to apply?

Eligibility is limited to U.S. small businesses.

Is cost sharing or matching required?

No cost sharing or matching requirement is stated for this opportunity in the provided information.

Is there a related STTR opportunity with the same scientific scope?

Yes. A parallel announcement with identical scientific scope exists under the Small Business Technology Transfer (STTR) program: PA-09-114, using mechanisms R41/R42.

Why would an applicant consider the STTR version instead of the SBIR version?

Based on the provided information, the STTR structure may matter for applicants who want or need a formal research institution partner. Applicants can pursue essentially the same manufacturing-focused biomedical goals through SBIR or STTR depending on which mechanism better fits their team and commercialization strategy.

What funding activity categories are associated with this opportunity?

The announcement is associated with both education and health funding activity categories, reflecting NIH's interest in advancing health technologies and supporting the research capacity and know-how needed to deliver them.

What CFDA program areas are linked to this opportunity?

The listing ties the opportunity to a broad range of program areas, including oral health; hearing and communication disorders; sleep; mental health; substance use; technology innovation; research resources; multiple cancer research areas; cardiovascular and pulmonary diseases; blood disorders; arthritis and musculoskeletal conditions; neuroscience; immunology and transplantation; infectious diseases; general biomedical research and training; aging; and vision research.

Does the wide range of program areas mean manufacturing innovations can apply across many disease areas?

Yes. The broad mapping signals that manufacturing innovations are relevant across many NIH institutes and disease areas, and applicants can align proposals with the institute or program most connected to their product area and public health impact.

How are funding levels and the number of awards determined?

NIH notes that awards depend on the availability of funds and the receipt of enough meritorious applications. The total dollars and number of awards are not fixed in the provided summary and can vary based on proposal quality, proposed project periods, and requested budgets.

Is this a discretionary grant?

Yes. The announcement is categorized as a discretionary grant.

What is the connection to Executive Order 13329?

The focus on manufacturing comes directly out of Executive Order 13329 (signed February 26, 2004), which directed federal SBIR/STTR agencies to give high priority to manufacturing-related R&D as allowed by law and aligned with each agency's mission. NIH responded by encouraging SBIR applications that strengthen manufacturing readiness and capability across biomedical products and enabling technologies.

When was this opportunity posted, and is it still active?

It was posted and created on February 26, 2009. The original and current closing date was January 7, 2012, and the archive date was February 7, 2012. Based on those dates, it is no longer active as written.

Where can applicants find the official full announcement details?

NIH provided an additional information link to the full announcement on the NIH grants site. For access or linking issues, NIH referenced contact directions through the NIH Office of Extramural Research (OER) Webmaster email.

What kinds of manufacturing improvements might fit this FOA based on the description?

Examples consistent with the provided description include developing new fabrication methods for devices, improving process control and automation, advancing scale-up strategies for biological materials, designing specialized manufacturing equipment, and creating systems that increase output quality, throughput, reproducibility, and safety.

What is the main takeaway for potential applicants reviewing this archived FOA?

The main takeaway is that NIH used this opportunity to fund the engineering and manufacturing steps that help turn biomedical discoveries into dependable, producible technologies that can realistically reach patients, clinics, and laboratories.